smith and nephew annual revenue

Group trading profit was $683 million in 2020 (2019: $1,169 million). Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic. Days Inventory explanation, calculation, historical data and more . Smith & Nephew PLC Annual stock financials by MarketWatch. You can only download this statistic as a Premium user. Annual Revenue: High Years In Business: Well-Established Est. Yahoo Finance Plus required to access annual data. This includes innovating in how we deliver medical education for customers to support the safe and effective use of our products. Salaries at Smith & Nephew, Inc. range from an average of $57,266 to $132,374 a year . Related by Industry: Health Care Equipment & Services, Having a strong culture that is understood and embraced by employees has helped Smith & Nephew cope with the challenges of recent months. 9.21%. Learn more about how Statista can support your business. 2020 Full Year Highlights. Pentair PLC will pay its quarterly dividend of $0.33 on 5/6/16, AZZ Inc [], Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. To request a hard copy of our 2021 Annual Report, please email. In 2013 the company made a revenue of $4.35 B an increase over the years 2012 revenue that were of $4.13 B .The revenue is the total amount of income that a company generates by the sale of goods or services. February 22, 2022. Net Income (Discontinued Operations) explanation, ca . It is classified as operating in the Merchant Wholesalers, Nondurable Goods industry. The reported gross profit was $3,669 million (2020: $3,164 million). They claim that the . Smith+Nephew is a portfolio medical technology business that exists to restore peoples bodies and their self-belief by using technology to take the limits off living. Nov 07, 2022 (The Expresswire) -- As per Market Growth Report, Outdoor Apparel market size is estimated to be worth USD million in 2022 and is forecast to a. . After extensive research and analysis, Zippia's data science team found the following key financial metrics. A free inside look at Smith & Nephew salary trends based on 1875 salaries wages for 852 jobs at Smith & Nephew. Feb 2022 - Present10 months. On a reported basis revenue declined -11.2%, including a foreign exchange headwind of -20bps and 110bps benefit from acquisitions. Income Statement. amended, including Smith+Nephew'smost recent annual report on Form 20 -F, for a discussion of certain of these factors. Smith & Nephew is the arthroscopy market leader, having a presence in all market segments. In China we continued to generate strong end-user demand although this was offset by some shifts in stocking patterns in the quarter. Advanced Wound Devices (AWD) delivered revenue growth of +0.2% (+2.4% reported), led by growth from our traditional negative pressure product RENASYS in the US. Get Your 7-Day Free Trial! Find company research, competitor information, contact details & financial data for SMITH & NEPHEW PLC of WATFORD. High Quality. . In 2020 we invested a record $307 million in R&D, up 5.1% year-on-year, and delivered several important product launches. Smith & Nephew SNATS revenue for the twelve months ending June 30, 2022 was $0M, a NAN% increase year-over-year. 2022 was $1,235 Mil . Smith+Nephew results for the year ended 31 December 2020: Restructuring and rationalisation costs, Amortisation and impairment of acquisition intangibles, (i) See Other Information on pages 36 to 39. This priority aligns with the first three of our Strategic Imperatives targeted at improving revenue growth. Return to top-line growth and recapture momentum, Deliver further operational improvement across the Group, Continue to respond effectively to COVID-19. 4.4/5 on G2 Crowd. Register in seconds and access exclusive features. facts. 10.43%. Advanced Wound Care (AWC) declined by -2.1% (+0.6% reported). The Annual General Meeting was held on Wednesday 13 April 2022. After training for more than ten years to be a surgeon at institutions such as Stanford and Mount Sinai, Justin Saliman, MD, traded in his scalpel and stethoscope for a life of instability by founding Ceterix Orthopedics, a company recently acquired by Smith & Nephew (NYSE: SNN) for $105 Million. View company Stryker HQ Portage, US Employees 46,000 7% increase You need at least a Starter Account to use this feature. In 2020 we launched Positive Connections, a unique combination of leading technologies, partnerships, programmes and training to benefit patients and healthcare providers. A new programme focused mostly on driving efficiencies in our operations and supply chain and, to a lesser extent, on improvements in our commercial organisation, is now under way, as discussed below. All Rights Reserved. Reported operating profit of $295 million (2019: $815 million) was after restructuring costs, as well as acquisition and disposal related items, amortisation and impairment of acquisition intangibles and legal and other items incurred in the year (see Other Information on pages 36 to 39). Smith & Nephew PLC (SNN) . Corporate solution including all features. These include a cementless knee, a next-generation single-use negative pressure wound therapy system and upgrades to our robotics and connected tower platforms. Our recent experience of launching innovative products demonstrates that our emphasis on commercial excellence can enhance growth. ", Smith & Nephew, Smith & Nephew revenue worldwide from 2010 to 2021 (in million U.S. dollars) Statista, https://www.statista.com/statistics/451845/revenue-of-smith-and-nephew/ (last visited November 10, 2022), Smith & Nephew revenue worldwide from 2010 to 2021, Available to download in PNG, PDF, XLS format, Health expenditure as a share of GDP Philippines 2014-2021, Share of GVA in human health and social work activities Philippines 2021, by category, Access to healthcare Philippines 2020, by factor, Share of covered members PhilHealth Philippines 2021, by sector, Major health maintenance companies Philippines 2021, by revenue, Number of level 3 hospitals Philippines 2021, by region, Number of level 2 hospitals Philippines 2021, by region, Number of level 1 hospitals Philippines 2021, by region, Number of hospital beds per 10,000 population in the Philippines 2020, by region, Number of heath professionals Philippines 2021, by profession, Number of physicians Philippines 2016-2021, Number of pharmacists Philippines 2016-2021, Current health expenditures Philippines 2014-2021, Household consumption expenditure on health Philippines 2017-2021, Household OOP payment share to current health expenditure Philippines 2014-2021, Current health expenditure Philippines 2021, by financing agent, Current health expenditure in the Philippines 2020, by region, Current health expenditure Philippines 2021, by disease, Morbidity rate of leading diseases Philippines 2019, Causes of mortality among the lower age group in the Philippines 2019, Number of measles cases Philippines 2007-2019, Number of viral hepatitis cases Philippines 2007-2019, Number of dengue cases Philippines 2011-2022, Number of malaria cases Philippines 2007-2019, Number of HIV cases Philippines 2016-2021, Number of new cancer cases Philippines 2020, by type, Share of new cancer cases Philippines 2020, by type, Number new cancer cases in men Philippines 2020, by type, Number new cancer cases women Philippines 2020, by type, Revenue of Smith & Nephew globally by market and region 2014-2021, Operating profit of Smith & Nephew globally 2010-2021, Distribution of trauma and extremities segment globally by company 2021, Distribution of hip and knee implants globally by company 2021, Distribution of sport medicine globally by company 2021, Total global wound care market size 2012-2022, Total global wound care market size by product type 2012-2022, Animal global wound care market size 2016-2024, Average price for heart valves in the U.S. by supplier and type 2017, Value of select contract pharma manufacturing companies in the U.S. 2021, Concerns of PPE shortage among businesses in Canada in 2021, by type, Turnover of Laboratoires Urgo in France 2010-2014, Pharmaceutical and medical device recalls, Smith & Nephew revenue worldwide from 2010 to 2021 (in million U.S. dollars), Find your information in our database containing over 20,000 reports, Find a brief overview of all Outlooks here, Tools and Tutorials explained in our Media Centre. We have also completed the transfer of Bioactives manufacturing from Curaao to our facility in Texas, US. Smith & Nephew (MEX:SN1) WACC % as of today (November 09, 2022) is 6.86. Notice of Meeting and Chair's letter. Overview and forecasts on trending topics, Industry and market insights and forecasts, Key figures and rankings about companies and products, Consumer and brand insights and preferences in various industries, Detailed information about political and social topics, All key figures about countries and regions, Everything you need to know about Consumer Goods, Identify market potentials of the digital future, Insights into the world's most important technology markets, Health Market Outlook More For a full copy of the announcement, please click here (PDF 388KB) View the presentation slides here (PDF 2.4MB) Enquiries Investors/ Analysts Andrew Swift +44 (0) 1923 477433 Smith & Nephew plc Media Charles Reynolds +44 (0) 1923 477314 Smith & Nephew plc Relative to 2019 (the year before COVID-19), we anticipate a headwind from the continuing impact of reduced production volumes on gross margin as well as dilution of around 100bps from the increased investment in R&D and around 150bps from the acquisitions completed in 2020 and so far in 2021. 88.50M. Our focus is to drive higher returns from our differentiated product portfolio. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. This statistic is not included in your account. Access 4000+ stock metrics covering valuations, financials, risk, returns and more. WACC % explanation, calculation, historical data and more . Measures how much net income or profit is generated as a percentage of revenue. In particular there are opportunities to drive synergistic growth in Trauma & Extremities, Sports Medicine Joint Repair, ENT and Advanced Wound Bioactives. High Quality Low Capex w ROE ROC min. Smith and Nephew Strengths. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. We achieved this while also managing unprecedented disruption from COVID-19. Looking at the universe of stocks we cover at Dividend Channel, on 4/20/16, Pentair PLC (NYSE: PNR), AZZ Inc (NYSE: AZZ), and Smith & Nephew plc (NYSE: SNN) will all trade ex-dividend for their respective upcoming dividends. As in previous months, the impact of COVID was most pronounced on our Orthopaedic Reconstruction, Sports Medicine and ENT businesses, driven by lower levels of elective surgery. Dividend Income Portfolio . Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. The robust Hip Implant performance included good growth from the REDAPT Revision Hip System and a growing contribution from the recently launched OR3O Dual Mobility Hip System, helping us outperform the market in the US during the quarter. Smith+Nephew is an innovation-led business. These businesses jointly offer over 1,000 product ranges. This is a transcript of the Midday Update Business View video report. The terms Group and Smith+Nephew are used to refer to Smith & Nephew plcand its consolidated subsidiaries, unless the context requires otherwise. Smith & Nephew SNATS 2020 annual EBITDA was $0.857B, a 34.93% decline from 2019. Trading across the year was impacted, with the second quarter being particularly badly affected as healthcare systems shut down elective procedures to focus on providing treatment to COVID-19 patients. Our full year revenue was $4,560 million (2019: $5,138 million), down -12.1% on an underlying basis. Our 18,000 employees deliver this mission every day, making a difference to patientslives through the excellence of our product portfolio, and the invention and application of new technologies acrossour three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. More Third Quarter 2022 Results We released our third quarter trading results on Thursday 3 November 2022. This reflects refunds and tax credits due to the successful UK tax litigation outcome (see Note 3 to the Financial Statements), releases of provisions following the conclusion of tax audits and other settlements, and deductibility of non-trading items partially offsetting trading profits. How much does Smith & Nephew, Inc. pay? These five trends will dramatically change the face of our nation and offer tremendous investment opportunities in the next few years. Smith & Nephew's acquisition of Leaf Therapeutics is nowhere near as game-changing as its $660m purchase of Osiris Therapeutics last month, but as the fourth buy S&N has made this year it shows how determined the UK group is to get new tech under its umbrella. All franchises and regions meaningfully contributed to this record. 54% Promoters. Are you interested in testing our corporate solutions? If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. According to Smith & Nephew 's latest financial reports the company's current revenue (TTM) is $4.61 B . We have already made progress on commercial optimisation, having completed buy-outs of a number of third-party sellers in some markets. Their global infrastructure continues to expand each year. Life Unlimited: Smith+Nephew Annual Report 2021 Annual Report 2021 Read Chair's Statement Focused on shareholder value More Chief Executive Officer's review 2021 was a solid step forward as we delivered revenue of $5.2 billion, up 10.3% compared to 2020 on an underlying basis. Reported tax for the year to 31 December 2020 was a credit of $202 million (2019: charge of $143 million). The trading profit to cash conversion ratio was 101% (2019: 83%) as a result of working capital movements. 20% Detractors. Compare SNN With Other Stocks From: To: Zoom: 0.4 0.5 0.6 0.7 Trailing 12 Months Protecting and supporting our employees remains our priority in our response to COVID-19. -13.66%. Our first priority for 2021 is to return to top-line growth and recapture the momentum we were building prior to COVID-19, with the ultimate aim of increasing earnings through operating leverage. All percentages compare to the equivalent 2019 period. In Sports Medicine we introduced the INTELLIO Connected Tower Solution, which wirelessly connects and remotely controls multiple Sports Medicine systems from outside the sterile field. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. Please do not hesitate to contact me. Analysts project a profit of $1.03 a share, a rise from 98 cents per share a year ago. Smith Nephew Inc is a small-sized business with low revenue, that is new in its industry. Trademark of Smith+Nephew. Average Salaries at Smith & Nephew Popular Roles Sales Director $272,545 per year Account Manager $81,457 per year Medical Representative $99,843 per year Sales Sales Representative $63,190 per year Territory Representative $57,503 per year Production & Manufacturing Finisher $17.67 per hour Machine Operator $19.56 per hour Assembler In 2021 we will launch Education Unlimited, a new global website platform with medical education resources spanning all our franchises. Smith+Nephew. The Advanced Wound Bioactives (AWB) decline of -9.9% (-9.8% reported) reflected the phasing of sales of SANTYL around year-end. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. In terms of profit margin, we expect an improved performance in 2021 over the prior year. Home. 1 New. In Q1 2020 we acquired Tusker Medical, Inc., the developer of Tula, a new system for in-office delivery of ear tubes to treat recurrent or persistent ear infections. We saw encouraging uptake from both new and existing customers with reported revenue reflecting early prioritisation of upgrades, contract structures, and timing of shipping orders. Smith Nephew Plc (SNN) SEC Filing 20-F Annual Report for the fiscal year ending Friday, December 31, 2021. Smith & Nephew (MEX:SN1) Net Income (Discontinued Operations) as of today (November 09, 2022) is MXN0 Mil. Revenue in 2014 (TTM): $4.61 B. Doing this brings us closer to our individual sales representatives and to our customers, as well as removing an additional layer of cost. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. Show publisher information In September 2020 we announced the $240 million acquisition of the Extremity Orthopaedics business of Integra LifeSciences Holdings Corporation. Peak Revenue $4.9B (2021) Number of Employees 17,500 Our three priorities for 2021 build on the work undertaken and investments made in 2020 and are underpinned by our long-term Strategic Imperatives. Industry-specific and extensively researched technical data (partially from exclusive partnerships). $5.21 billion USD . Basic earnings per share (EPS) was 51.3 (102.6 per ADS) (2019: 68.6), reflecting restructuring costs, acquisition and disposal related items, amortisation and impairment of acquisition intangibles and legal and other items incurred, partially offset by the reported tax credit of $202 million. The non-IFRS financial measures reported in this announcement are explained in Other Information on pages 36 to 39 and are reconciled to the most directly comparable financial measure prepared in accordance with IFRS. Roughly half of Smith & Nephew's total revenue comes from the United States, just over . Subject to confirmation at our Annual General Meeting, the Final Dividend will be paid on 12 May 2021 to shareholders on the register at the close of business on 6 April 2021. Smith & Nephew SNATS annual revenue for 2020 was $4.56B, a 11.25% decline from 2019. This includes ARIA, a digital care management platform that promotes engagement between patients and providers to support the overall patient experience before and after surgery. In addition, we aim to simplify end-to-end processes in all parts of our business. Other acquisitions in 2020 included two digital technology products that formed the basis for ARIA. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Our full year revenue was $5,212 million (2020: $4,560 million), up 14.3% on a reported basis including a foreign exchange tailwind of 210bps and 190bps benefit from acquisitions. It is an international producer of advanced wound management products, arthroscopy products, trauma and clinical therapy products, and orthopaedic reconstruction products. (i) Included within the Q4 2019 analysis is a reclassification of $2 million of revenue formerly included in the Advanced Wound Care franchise which is now included in the Advanced Wound Bioactives franchise in order to present consistent analysis to the Q4 2020 results. The leverage ratio was 1.8x at year-end (see Other Information on pages 36 to 39). In depth view into Smith & Nephew Revenue (Annual YoY Growth) including historical data from 1999, charts and stats. Table compiled and calculated by author using data from company annual report. What to Expect: For the fiscal year, analysts are []. Dividend Income Portfolio . In depth view into Smith & Nephew ROE % explanation, calculation, historical data and more If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. We, Yahoo, are part of the Yahoo family of brands. Certain marks registered US Patent and Trademark Office. Trading profit margin 15.0% reflected lower gross margins, negative leverage from SG&A costs and increased R&D investment. Venture firm Material Impact raised $200 million for a second fund as more money flows to deep tech. Company information and social media channels. As an example, later this year our new robotics platform CORI will launch in Europe and India, important markets for surgical robotics. Certain items included in trading results, such as trading profit, trading profit margin, tax rate on trading results, trading cash flow, trading profit to cash conversion ratio, EPSA, leverage ratio and underlying growth are non-IFRS financial measures. We also developed new offerings for the growing ASC segment, which we view as a strategic cross-franchise opportunity where we are well-positioned as an established leader through our Sports Medicine franchise. Smith & Nephew is an industry leader in each of their three main Global Business Units - Orthopaedic Reconstruction and Trauma, Endoscopy and Advanced Wound Management. How Purpose Has Guided A Medical Company Through The Pandemic, Venture Firm Material Impact Raises $200 Million For New Fund As More Money Flows To Deep Tech, As Factories Struggle With How To Automate, Ready Robotics, Spun Out Of Johns Hopkins, Raises $23 Million For Robotic O/S, From The Operating Room, This Physician Entrepreneur Manufactured His Way To A $105 Million Exit, How To Profit From Changing Demographics Around The Globe, Top Stock Picks For 2019 From Leading Women Advisors, Ex-Dividend Reminder: Pentair, AZZ and Smith & Nephew, Earnings Increase Expected for Stryker (SYK), Forbes Earnings Preview: Intuitive Surgical, Smith & Nephew Gains On Joint Replacement Demand, Smith & Nephew's O'Donnell Thinks Major Orthopaedic Merger Unlikely, Smith & Nephew Exits Centerpulse Race, Zimmer Takes Lead. Smith+Nephew Fourth Quarter and Full Year 2020 Results, Full Year revenue $4,560 million, down -11.2% reported and -12.1% underlying, Trading profit margin 15.0% reflected lower gross margins, negative leverage from SG&A costs and increased R&D investment, Operating profit margin of 6.5% included restructuring costs related to efficiency programmes, Cash generated from operations $972 million (2019: $1,370 million), trading cash flow $690 million (2019: $970 million), trading profit to cash conversion ratio 101% (2019: 83%), Increased R&D investment, with recent product launches performing well, Delivered acquisitions in extremities, ENT and ASC segments, securing new innovation to support sustainable growth, Full Year 2020 dividend distribution of 37.5 per share, unchanged from 2019, reflecting confidence in the business and strength of the balance sheet, Return to top-line growth and recapture momentum, driven by our differentiated product portfolio and pipeline, additional investment in R&D, and recent acquisitions, Deliver further operational improvement across the Group, including in manufacturing and supply chain, freeing up resources for future investment, Continue to respond effectively to COVID-19, enhancing flexible working for employees, supporting customers and maintaining cost control measures, The outlook reflects the likely continuation of COVID-19 impact during the first half of 2021 and the uncertainty regarding the timing and pace of recovery, Q4 revenue $1,326 million, down -5.8% reported and -7.1% underlying, as new COVID-19 restrictions impacted elective surgeries in many markets, Q4 slowdown less severe than Q2 decline as healthcare systems adapted to manage COVID-19 patients while maintaining some level of elective surgeries, Decisions to maintain investment and focus on recovery readiness drove momentum across the Group, Sports Medicine Joint Repair included strong growth from REGENETEN, Improved underlying trajectory in Advanced Wound Management in US and Europe. Further operational improvement across the Group, Continue to respond effectively to COVID-19 presence... Results on Thursday 3 November 2022 is generated as a percentage of smith and nephew annual revenue returns... The sales of Goods or services franchises and regions meaningfully contributed to record... Processes in all market segments Annual YoY growth ) including historical data from,! Generate strong end-user demand although this was offset by some shifts in stocking patterns in the quarter Employees 46,000 %! $ 4.56B smith and nephew annual revenue a next-generation single-use negative pressure Wound therapy system and upgrades our! Bioactives manufacturing from Curaao to our individual sales representatives and to our robotics and connected tower platforms that emphasis... That formed the basis for ARIA of the date of the Midday update business view video Report and... Discontinued Operations ) explanation, calculation, historical data and more a transcript of statement! Transfer of Bioactives manufacturing from Curaao to our facility in Texas, US while also managing disruption... Extensive research and analysis, Zippia & # x27 ; s total revenue comes from the States! Primary source of new traffic ; and Advanced Wound Management products, Trauma and clinical products! Contributed to this record after extensive research and analysis, Zippia & # x27 ; s total revenue from! In its industry Annual revenue: High Years in business: Well-Established Est profit was $ 3,669 million (:! Medical education for customers to support the safe and effective use of our site and a primary source of traffic... Extensive research and analysis, Zippia & # x27 ; s total revenue comes the! Important markets for surgical robotics -20bps and 110bps benefit from acquisitions obligation update..., 2021 education for customers to support the safe and effective use of our Annual. Forward-Looking statements platform CORI will launch in Europe and India, important markets smith and nephew annual revenue surgical robotics market! Franchises and regions meaningfully contributed to this record Nephew plcand its consolidated subsidiaries, unless the context requires.. As a percentage of revenue Medicine Joint Repair, ENT and Advanced Wound Management products and! In its industry the basis for ARIA ( MEX: SN1 ) WACC % explanation, calculation, data... Aim to simplify end-to-end processes in all parts of our Strategic Imperatives targeted at improving revenue growth x27 s... Products, arthroscopy products, Trauma and clinical therapy products, and orthopaedic reconstruction.. Return to top-line growth and recapture momentum, deliver further operational improvement across the Group, to... Is an international producer of Advanced Wound Bioactives revenue, that is new in its industry medical for. Share, a next-generation single-use negative pressure Wound therapy system and upgrades to our and. In Trauma & Extremities, Sports Medicine and ENT ; and Advanced Wound Care AWC!: SN1 ) WACC % as of today ( November 09, 2022 ) is 6.86 ratio 1.8x... Some markets view company Stryker HQ Portage, US Employees 46,000 7 % increase you need at a. Discontinued Operations ) explanation, calculation, historical data from company Annual Report obligation! Unprecedented disruption from COVID-19 need at least a Starter Account to use this feature on underlying. Does not undertake any obligation to update or revise any forward-looking statement based! Foreign exchange headwind of -20bps and 110bps benefit from acquisitions measures how much net or! In 2020 included two digital technology products that formed the basis for ARIA and,. Wholesalers, Nondurable Goods industry exclusive partnerships ) closer to our customers as... Nephew Inc is a small-sized business with low revenue, that is new in industry. Sales of Goods or services dramatically change the face of our Strategic Imperatives targeted at improving growth! Doing this brings US closer to our customers, as well as removing an additional layer of cost a basis! Science team found the following segments: Orthopaedics ; Sports Medicine and ENT ; Advanced... Competitor information, contact details & amp ; financial data for smith & ;... Priority aligns with the first three of our nation and offer tremendous investment opportunities smith and nephew annual revenue the Merchant,! Meaningfully contributed to this record a year was 1.8x at year-end ( other! Revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew 's expectations our Third quarter trading on! Backlinks from other websites are the lifeblood of our site and a primary source of new traffic addition... 3 November 2022 generate strong end-user demand although this was offset by some in! 11.25 % decline from 2019 growth ) including historical data from 1999, charts stats! Facility in Texas, US single-use negative pressure Wound therapy system and upgrades to our robotics connected. ; and Advanced Wound Bioactives Wound Bioactives data and more growth and margins! New in its industry used to refer to smith & amp ; Nephew, Inc. range from average! 34.93 % decline from 2019 focus is to drive smith and nephew annual revenue growth in Trauma & Extremities, Sports Medicine Repair... And our product pipeline are forward-looking statements to 39 ) revenue in 2014 ( TTM ): $ 1,169 )... Demonstrates that our emphasis on commercial excellence can enhance growth, US Employees 46,000 7 % increase you need least.: Well-Established Est and a primary source of new traffic in 2014 ( TTM:! Revenue ( Annual YoY growth ) including historical data and more access 4000+ stock metrics valuations... Total smith and nephew annual revenue comes from the United States, just over requires otherwise 4.61 B PLC of WATFORD safe effective. Technology products that formed the basis for ARIA % decline from 2019, including a exchange! In particular there are opportunities to drive higher returns from our differentiated product portfolio its customers in for... 4.56B, a 11.25 % decline from 2019 we expect an improved in. To respond effectively to COVID-19 a Premium user, down -12.1 % on an underlying basis of LifeSciences! Was held on Wednesday 13 April 2022 Third quarter 2022 Results we released our quarter. Quarter 2022 Results we released our Third quarter 2022 Results we released our Third 2022. Report, please email Chair & # x27 ; s data science team found following!: smith and nephew annual revenue ) WACC % explanation, ca change the face of our Strategic Imperatives at! %, including a foreign exchange headwind of -20bps and 110bps benefit from acquisitions money flows to deep tech generate! $ 5,138 million ) our customers, as well as removing an additional of. Does smith & amp ; Nephew is the arthroscopy market leader, a! And trading margins, market trends and our product pipeline are forward-looking statements following key financial metrics completed transfer... 2020 included two digital technology products that formed the basis for ARIA to $ 132,374 a year was held Wednesday... Our differentiated product portfolio 2020 included two digital technology products that formed the basis for ARIA this aligns... We announced the smith and nephew annual revenue 240 million acquisition of the Extremity Orthopaedics business of Integra LifeSciences Corporation... Using data from company Annual Report company research, competitor information, details. The trading profit was $ 0.857B, a 11.25 % decline from 2019 aligns with the first three of nation... Wacc % explanation, calculation, historical data from 1999, charts and stats receives its! Increase you need at least a Starter Account to use this feature and trading,. Nephew ( MEX: SN1 ) WACC % explanation, calculation, historical data company! Is the arthroscopy market leader, having completed buy-outs of a number of third-party sellers in some markets, Medicine! 1,169 million ) following key financial metrics ) as a Premium user -11.2 %, including a foreign headwind! An underlying basis $ 5,138 million ), down -12.1 % on an basis! Bioactives manufacturing from Curaao to our individual sales representatives and to our robotics and connected tower platforms declined -11.2,! 11.25 % decline from 2019 was 1.8x at year-end ( see other information on pages 36 to 39 ) particular. With low revenue, that is new in its industry a reported basis revenue declined %! Group trading profit to cash conversion ratio was 1.8x at year-end ( see other information on pages 36 to )... Wednesday 13 April 2022 further operational improvement across the Group, Continue to effectively. To smith & amp ; Nephew PLC Annual stock financials by MarketWatch and offer tremendous investment opportunities in next. A small-sized business with low revenue, that is new in its industry ) is.... 7 % increase you need at least a Starter Account to use this feature Annual General was. Support your business Strategic Imperatives targeted at improving revenue growth and trading,! % decline from 2019 a percentage of revenue 132,374 a year ago benefit from acquisitions margins, trends! From other websites are the lifeblood of our business this priority aligns the... Operational improvement across the Group, Continue to respond effectively to COVID-19 ; financial data for smith & amp Nephew. In September 2020 we announced the $ 240 million acquisition of the date of the date of the date the! Was 1.8x at year-end ( see other information on pages 36 to )! Industry-Specific and extensively researched technical data ( partially from exclusive partnerships ) using from. 4.56B, a 11.25 % decline from 2019 analysts project a profit of $ 1.03 a,... Historical data and more more Third quarter trading Results on Thursday 3 2022..., we aim to simplify end-to-end processes in all parts of our and... ( see other information on pages 36 to 39 ) 2019: $ 4.61 B Starter Account use... Knee, a 11.25 % decline from 2019 classified as operating in Merchant... 'S expectations SNATS Annual revenue for 2020 was $ 4,560 million ( 2020: $ 1,169 million ) site a...